top of page
Search

Evidence Shows Prenatal Paracetamol Does Not Cause Neurodevelopmental Issues (Lancet)

Baby booties, acetaminophen bottle, and open notebook with pen on wooden table. Tablet in background shows study titled "Study Finds No Link."

*this article is for informational purposes only and does not constitute medial advice.


1. Introduction: The Clinical Dilemma of Pain & Fever Relief in Expectant Mothers

In the pantheon of modern medicine, few pharmaceutical agents occupy as central a role in the daily lives of the global population as paracetamol (known in North America as acetaminophen). For decades, it has been the pervasive, reflexively trusted solution for pain and fever, a status that is amplified during the vulnerable window of pregnancy. Estimates suggest that between 46% and 56% of pregnant women in developed nations utilize this analgesic at some point during their gestation.1 It is the default recommendation of obstetricians, midwives, and pharmacists, not merely because of its efficacy, but because of the stark and dangerous contraindications associated with its alternatives.

However, for the better part of the last decade, this foundational pillar of obstetric care has been shaking. A creeping accumulation of observational data began to suggest a terrifying possibility: that the very drug used to protect the pregnancy from the harms of fever and pain might be silently altering the neural architecture of the fetus. An increasing number of epidemiological studies reported statistical associations between prenatal paracetamol exposure and the subsequent diagnosis of neurodevelopmental disorders, specifically Autism Spectrum Disorder (ASD), Attention-Deficit/Hyperactivity Disorder (ADHD), and intellectual disabilities.

This potential signal precipitated a crisis of confidence that rippled through the medical community and regulatory bodies. Amplified by recent leadership change of US Health Agencies who promoted unfounded claims, this caused much anxiety in the minds of expectant parents. It fueled high-profile litigation in the United States, prompted a controversial (and heavily discredited) "Consensus Statement" from a group of unqualified scientists calling for precautionary restrictions, and left clinicians in an impossible bind. If paracetamol was dangerous, but high fever and NSAIDs were also dangerous, what was the safe path?

The resolution to this decade-long anxiety has arrived in the form of a landmark systematic review and meta-analysis published on January 16, 2026, in The Lancet Obstetrics, Gynaecology, & Women’s Health.2 This study, led by Francesco D'Antonio and a team of international researchers, represents the most rigorous synthesis of evidence to date. By prioritizing methodology that controls for the complex interplay of genetics and family environment—specifically the "sibling comparison" design—this new research provides compelling evidence that the previously observed associations were not causal. They were, instead, sophisticated mirages created by the underlying conditions the drug was treating and the shared genetic heritage of mother and child.

This report serves as a deep-dive analysis of this pivotal moment in perinatal epidemiology. It will explore the historical context of the controversy, dissect the biological and statistical mechanisms at play, detail the findings of the 2026 review, and articulate the profound implications for clinical practice and public health policy.

2. The Context of the Controversy: A Perfect Storm

To understand the significance of the D'Antonio et al. review, one must first appreciate the fertile ground in which the "paracetamol-autism" hypothesis took root. The early 21st century has been characterized by a dramatic and largely unexplained rise in the prevalence of neurodevelopmental disorders.

2.1 The Rising Tide of Neurodevelopmental Diagnoses

From 2000 to 2020, the prevalence of Autism Spectrum Disorder diagnoses rose precipitously, with recent estimates from the CDC suggesting rates as high as 1 in 36 children.3 Similarly, diagnoses of ADHD increased by approximately 36% between 2003 and 2016.3 While much of this increase can be attributed to better diagnostic criteria, increased awareness, and the destigmatization of neurodivergence, the sheer velocity of the trend spurred an intense scientific search for environmental contributors.

Researchers looked for ubiquitous exposures—chemicals or drugs that had become more common in parallel with the rise in diagnoses. Paracetamol fitted this profile perfectly. Its use had expanded significantly following the discovery of the association between aspirin use in children and Reye's syndrome in the 1980s, which effectively removed aspirin from the pediatric and obstetric cabinet for routine pain relief.

2.2 The Observational Signal

The hypothesis was initially supported by a series of observational cohort studies. These studies typically followed a simple design: recruit a large group of pregnant women, ask them (via questionnaires or interviews) if they took paracetamol, and then assess their children years later for behavioral issues.

The results were tantalizingly consistent. A meta-analysis of such studies, prior to the rigorous 2026 review, suggested that children exposed to the drug in utero were approximately 20% to 30% more likely to be diagnosed with ADHD or ASD.1 For instance, a collaborative study of six European cohorts published in the European Journal of Epidemiology in 2021 found that prenatal exposure was associated with a 19% increased likelihood of ASD symptoms and a 21% increased likelihood of ADHD symptoms.1

These studies generally adjusted for standard confounding variables such as maternal age, smoking status, alcohol use, and socioeconomic status. When the association remained statistically significant after these adjustments, many researchers—and certainly the media—began to interpret the link as potentially causal.

2.3 The 2021 Consensus Statement

The scientific concern culminated in September 2021 with the publication of a document that would become the focal point of the debate: a "Consensus Statement" in Nature Reviews Endocrinology.6 Signed by 91 scientists, clinicians, and public health professionals, the statement declared that the "growing body of research suggests that prenatal exposure to paracetamol might alter development."

The authors of the statement called for "precautionary action." They recommended that pregnant women should:

  1. Forego paracetamol unless its use is medically indicated.

  2. Consult with a physician or pharmacist before using it.

  3. Minimize exposure by using the lowest effective dose for the shortest possible time.

While these recommendations mirror standard pharmacovigilance for any drug in pregnancy, the context—linking the drug specifically to autism and ADHD—was explosive. It effectively shifted the burden of proof. Paracetamol was no longer "innocent until proven guilty"; it was now a "suspect" that required justification for use.

Critics of the statement, including the European Medicines Agency (EMA) and various obstetric organizations, pointed out that the signatories included basic scientists and toxicologists but lacked representation from key clinical obstetric bodies or teratology information services.9 They argued that the statement induced unnecessary anxiety without providing a viable alternative for treating pain and fever, conditions which themselves carry known risks to the fetus.

3. The 2026 Prenatal Paracetamol Lancet Study: A Methodological Watershed

The study published in The Lancet Obstetrics, Gynaecology, & Women’s Health in January 2026 was explicitly designed to adjudicate this dispute.2 Titled "Prenatal paracetamol exposure and child neurodevelopment: a systematic review and meta-analysis," the research was led by Dr. Francesco D'Antonio and a team from City St George's, University of London.10

This was not merely another meta-analysis adding more low-quality studies to the pile. It was a "methodological intervention" designed to filter the evidence based on quality and the ability to control for unmeasured confounding.

3.1 Study Design and Hierarchy of Evidence

The review analyzed 43 studies, encompassing millions of pregnancies.2 However, rather than treating all data points as equal, the researchers established a hierarchy of evidence quality to separate the "signal" from the "noise."

They stratified the studies into three categories of rigor:

  1. Sibling-Comparison Studies: This was the crucial innovation. By analyzing siblings born to the same mother—one exposed to paracetamol and one unexposed—researchers could control for all stable family factors. This includes the mother's genetic makeup, her socioeconomic status, the neighborhood environment, and general parenting style. If paracetamol were a true teratogen, the exposed sibling should consistently show worse outcomes than the unexposed sibling, regardless of the shared family DNA.

  2. Low Risk of Bias Studies: These were non-sibling studies that nevertheless employed rigorous statistical adjustments for a comprehensive set of confounders, including maternal mental health and indications for drug use.

  3. General Observational Studies: The broader pool of research that is susceptible to standard confounding.

3.2 The Results: Disappearance of the Signal

The findings of the 2026 review were striking. When the researchers looked at the entire pool of data, including the lower-quality studies, the small associations with ASD and ADHD remained visible. This confirmed that the "signal" exists in the raw observational data.

However, as they climbed the hierarchy of evidence, applying stricter controls for bias, the signal evaporated.

3.2.1 Autism Spectrum Disorder (ASD)

In the sibling-comparison studies—the gold standard for this inquiry—the association between prenatal paracetamol and autism was null. The Odds Ratio (OR) was 0.93 (95% Confidence Interval: 0.69–1.24; P = 0.63).11

  • Interpretation: An Odds Ratio of 1.0 implies no difference in risk. A result of 0.93 suggests the exposed children were actually slightly less likely to have autism, though the result is statistically non-significant (the confidence interval crosses 1.0). This effectively rules out a meaningful causal risk.

  • Low Bias Studies: When looking at all studies with a "low risk of bias," the result was similarly null: OR 1.03 (0.86–1.23; P = 0.78).11

3.2.2 Attention-Deficit/Hyperactivity Disorder (ADHD)

The results for ADHD followed the exact same pattern.

  • Low Bias Studies: The Odds Ratio was 0.97 (0.89–1.05; P = 0.49).11

  • Sibling Controls: Other sources referencing the same high-quality registry data (likely the Swedish and Norwegian cohorts included in the meta-analysis) reported Hazard Ratios dropping from ~1.05 in the full population to 0.98 (0.94–1.02) within sibling pairs.12

  • Conclusion: There is no evidence that paracetamol exposure increases the risk of ADHD when familial factors are accounted for.

3.2.3 Intellectual Disability

The analysis for intellectual disability also showed no association in the high-quality studies. The Odds Ratio was 1.11 (0.92–1.34; P = 0.28).11

3.3 Consistency and Durability

The authors noted that these null findings held true even in studies with long-term follow-up periods exceeding five years.10 This is a critical detail, as some critics had previously argued that neurodevelopmental deficits might be "latent" and only manifest in older children. The 2026 review refutes this, showing that the lack of association persists into school age.

The consistency of the null findings across the most rigorous designs led the authors to a definitive conclusion: the previously reported associations were likely driven by confounding factors rather than any direct toxic effect of the drug.2

4. Deconstructing the Bias: Why Past Studies Were Wrong

The Lancet review does more than just provide a new number; it offers an epidemiological autopsy of the previous false alarms. To understand why the earlier studies found a link that doesn't exist, we must understand the two primary villains of observational epidemiology: Indication Bias and Genetic Confounding.

4.1 Confounding by Indication: The Fever Effect

In pharmacoepidemiology, "indication bias" occurs when the reason a patient takes a drug is itself a cause of the adverse outcome. Women do not take paracetamol during pregnancy for recreational purposes. They take it because they are unwell. The primary indications are fever (pyrexia), infection, and pain.

The Neurotoxicity of Inflammation

Extensive research into "Maternal Immune Activation" (MIA) has established that systemic inflammation during pregnancy can alter fetal brain development.

  • Fever as a Teratogen: High maternal fever, particularly in the first trimester, is a well-recognized risk factor for neural tube defects and has been linked to increased risks of autism and schizophrenia.13

  • The Cytokine Storm: When a mother fights an infection, her body releases pro-inflammatory cytokines such as Interleukin-6 (IL-6). These cytokines can cross the placenta (or stimulate placental cytokine production) and interact with the developing fetal brain, potentially altering microglial activation and neuronal pruning.15

Therefore, when an observational study sees a correlation between "Maternal Paracetamol Use" and "Child Autism," it is inextricably seeing a correlation between "Maternal Infection/Fever" and "Child Autism." The paracetamol is merely a marker for the inflammatory event. In reality, by reducing the fever, the paracetamol might be mitigating the damage, but simple correlations cannot distinguish the cure from the disease.

4.2 Genetic Confounding: The Hidden Variable

The second, and perhaps more insidious, source of bias is genetic. Autism and ADHD are highly heritable conditions, with heritability estimates ranging from 70% to 80%.

The ADHD-Pain Overlap

Recent breakthroughs in psychiatric genetics have revealed a significant genetic correlation between ADHD and chronic pain sensitivity. This phenomenon, often termed "Maternal Chronic Pain" (MCP) in the literature, provides the missing link.

  • The Mechanism: Mothers who carry genetic risk variants for ADHD are also biologically more sensitive to pain or more prone to chronic pain conditions (e.g., migraine, back pain).18

  • The Behavior: Because of this increased pain burden, these mothers are more frequent users of analgesics like paracetamol during pregnancy.

  • The Transmission: These mothers pass their genetic risk variants for ADHD to their children.

In a standard study, this looks like a drug effect: The mother took the drug, and the child got ADHD. But the drug was incidental. The child inherited the ADHD from the mother, who took the drug because her ADHD-related genetics made her more pain-sensitive.

The Sibling Comparison design employed in the Lancet review is the mathematical antidote to this problem. Because siblings share the same mother (and thus the same stable genetic and environmental risks), comparing them cancels out the maternal genetic contribution. If the drug were the cause, the sibling exposed to paracetamol should have ADHD while the unexposed one does not. The data showed that within families, the risk was equal regardless of exposure, proving that the shared genetics/environment were the true drivers.20

5. Biological Plausibility: Examining the Toxicological Theories

While the epidemiological data now largely exonerates paracetamol, the controversy was sustained for years by plausible biological theories. It is important to address why these theoretical risks did not translate into clinical reality.

5.1 The Oxidative Stress Hypothesis

Paracetamol is metabolized in the liver. A small fraction is converted by cytochrome P450 enzymes into a reactive metabolite called N-acetyl-p-benzoquinone imine (NAPQI). In overdose scenarios, NAPQI depletes the body's stores of glutathione (a major antioxidant), leading to liver cell death.

  • The Fear: Critics argued that even at therapeutic doses, NAPQI might cross the placenta and deplete glutathione in the fetal brain, leaving it vulnerable to oxidative stress.23

  • The Reality: The human fetus has a relatively immature cytochrome P450 system, meaning it produces very little NAPQI itself. Furthermore, at therapeutic doses, the maternal liver efficiently detoxifies NAPQI before it accumulates. The transfer of glutathione precursors from mother to fetus appears sufficient to protect the fetal brain under normal dosing conditions.

5.2 The Endocannabinoid Disruption Theory

Paracetamol also has a secondary mechanism of action involving the endocannabinoid system (ECS). One of its metabolites, AM404, inhibits the reuptake of anandamide (an endogenous cannabinoid) and activates TRPV1 receptors.

  • The Fear: Since the ECS plays a role in guiding neurons to their correct locations in the developing brain (neuronal migration), interfering with this system could theoretically lead to "mis-wiring" of neural circuits.23

  • The Reality: This effect is dose-dependent and transient. Animal models that showed harm often used high doses during critical windows of brain development that span only days in rodents but months in humans. The redundancy and plasticity of the human fetal brain likely buffer it against the transient pharmacological shifts caused by occasional paracetamol use.

6. The Legal and Regulatory Landscape

The scientific debate over paracetamol did not stay in the laboratory; it spilled into the courtroom and the regulatory offices, creating a high-stakes battle over liability and labeling.

6.1 The Tylenol Autism Litigation

In the United States, a massive Multi-District Litigation (MDL) was consolidated in the Southern District of New York. Thousands of plaintiffs sued retailers (like Walmart, CVS) and manufacturers, alleging that prenatal exposure to acetaminophen caused their children's autism and ADHD. The core legal argument was "failure to warn"—that the companies knew of the risk but failed to put it on the label.24

The litigation hinged on whether the scientific evidence was strong enough to prove "general causation"—that is, can the drug cause the condition in the general population?

6.2 The Daubert Ruling (2023)

In late 2023, the presiding judge, Judge Denise Cote, issued a decisive ruling under the Daubert standard, which governs the admissibility of expert testimony in federal court. After reviewing the available science, she excluded the plaintiffs' expert witnesses.

  • The Reasoning: Judge Cote found that the experts had "cherry-picked" observational studies and failed to adequately account for the limitations of that data—specifically the confounding factors discussed above. She noted that the experts ignored the high-quality studies (like the sibling comparisons) that showed no link.24

The 2026 Lancet study effectively serves as a post-hoc validation of Judge Cote’s legal reasoning. It provides the peer-reviewed, "gold standard" confirmation that the dismissal of the causal link was scientifically sound.

6.3 Regulatory Steadfastness

Throughout this turmoil, the major regulatory bodies—the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA)—remained remarkably consistent.

  • FDA: The FDA repeatedly reviewed the emerging literature and concluded that the evidence was "inconclusive" and suffered from "potential limitations" regarding study design.25 They refused to mandate a warning label for autism.

  • EMA: The European regulators were even more direct, stating there was "no evidence that taking paracetamol during pregnancy causes autism in children" and that it remained an "important option" for treatment.26

This divergence between the regulatory consensus (safe) and the academic/legal challengers (unsafe) created confusion, but the 2026 study has now unified the narrative.

7. Clinical Implications: The Danger of Alternatives

The most immediate practical outcome of the Lancet review is the restoration of clinical certainty. The fear of paracetamol had inadvertently pushed many pregnant patients toward far riskier behaviors.

7.1 The Risks of NSAIDs (Ibuprofen, Aspirin, Naproxen)

When patients avoid paracetamol, they often turn to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). While effective, these drugs have a safety profile in pregnancy that is objectively worse than paracetamol.

  • Third Trimester Contraindication: NSAIDs are strictly contraindicated in the third trimester (after 28 weeks). They work by inhibiting prostaglandins. In the fetus, prostaglandins are required to keep the ductus arteriosus open—a vital blood vessel that bypasses the fluid-filled lungs. NSAID use can cause this vessel to close prematurely, leading to pulmonary hypertension and heart failure in the newborn.28

  • Renal Failure: NSAIDs can also impair fetal kidney function, leading to low amniotic fluid levels (oligohydramnios), which can cause cord compression and poor lung development.30

  • Miscarriage Risk: Some data suggests NSAID use in the first trimester is associated with a higher risk of spontaneous abortion.

7.2 The Risk of Opioids

The other alternative for severe pain is opioid medication (codeine, oxycodone). While not teratogenic in the classic sense, opioids carry the risk of Neonatal Abstinence Syndrome (NAS), where the baby is born dependent on the drug and suffers withdrawal. They also pose a risk of maternal addiction and respiratory depression.

7.3 The Risk of Untreated Fever

Perhaps the most dangerous alternative is "therapeutic nihilism"—doing nothing. As noted earlier, untreated high fever is a proven teratogen. A mother who refuses paracetamol out of fear of autism, and subsequently sustains a high fever for days, is exposing her fetus to a confirmed risk (neural tube defects, seizures) to avoid a theoretical one.

7.4 Expert Recommendations

In light of the new evidence, experts like Dr. Brian Cleary of the Irish Medicines in Pregnancy Service and Prof. Grainne McAlonan of King’s College London have reinforced the standard advice 32:

  • First Line: Paracetamol remains the first-line treatment for pain and fever in pregnancy.

  • Indication: It should be used when there is a clinical need (it is not a placebo or a vitamin).

  • Dosing: Use the lowest effective dose for the shortest duration necessary to treat the symptom.

  • Reassurance: Pregnant women should not be distressed by past headlines. The best evidence shows no effect on neurodevelopment.

8. Conclusion: The Triumph of Rigor

The saga of paracetamol and autism serves as a potent case study in the evolution of epidemiological truth. It follows a classic trajectory: a frightening signal is detected in low-resolution data; biological theories are constructed to explain it; panic ensues; and finally, high-resolution data arrives to clarify the picture.

The 2026 systematic review by D'Antonio et al. represents that moment of clarity. By leveraging the power of large-scale registries and the elegance of the sibling-comparison design, the researchers were able to peel back the layers of confounding that had obscured the truth for a decade. They demonstrated that the "paracetamol effect" was actually a "genetics and fever effect."

For the clinician, this study authorizes a return to confident prescribing. Paracetamol is not a perfect drug—no drug is—but in the context of pregnancy, it remains the safest and most appropriate tool for managing the inevitable trials of pain and fever. For the expectant parent, the study offers a profound gift: the lifting of a burden. The anxiety that treating a headache might harm their unborn child was real and pervasive. Science has now provided the reassurance necessary to lay that anxiety to rest.

In the final analysis, the Lancet review confirms that while the rise in neurodevelopmental disorders is a genuine public health challenge, the solution does not lie in abandoning the most essential analgesic in the obstetric formulary.

Table 1: Comparative Safety Profile of Common Analgesics in Pregnancy


Drug Class

Examples

Trimester

Specific Fetal Risks

Clinical Status

Acetaminophen

Tylenol, Paracetamol

All

None Proven. (Associations with ASD/ADHD debunked by sibling studies).

First Line Choice. Safe for short-term use.

NSAIDs

Ibuprofen, Naproxen

1st & 2nd

Associated with miscarriage, gastroschisis.

Use with caution; avoid if possible.

NSAIDs

Ibuprofen, Naproxen

3rd

Premature Closure of Ductus Arteriosus, Oligohydramnios, Renal Failure.28

Contraindicated. Do not use.

Opioids

Codeine, Oxycodone

All

Neonatal Abstinence Syndrome (withdrawal), respiratory depression.

Second/Third line. Use only for severe pain.

Aspirin

Aspirin

3rd

Bleeding risks, Ductus Arteriosus closure (high dose).

Contraindicated (except low-dose 81mg for preeclampsia).



Table 2: Summary of Risk Estimates from D'Antonio et al. (2026)

11


Neurodevelopmental Outcome

Study Design Filter

Odds Ratio (95% CI)

P-Value

Interpretation

Autism Spectrum Disorder (ASD)

Sibling Comparison

0.93 (0.69 – 1.24)

0.63

No Association

Autism Spectrum Disorder (ASD)

Low Risk of Bias

1.03 (0.86 – 1.23)

0.78

No Association

ADHD

Low Risk of Bias

0.97 (0.89 – 1.05)

0.49

No Association

Intellectual Disability

Low Risk of Bias

1.11 (0.92 – 1.34)

0.28

No Association

Note: An Odds Ratio (OR) of 1.0 indicates no difference in risk between the exposed and unexposed groups. Confidence intervals that include 1.0 indicate the result is not statistically significant.

Works cited

  1. Prenatal exposure to paracetamol associated with increased risk of autism and ADHD, accessed January 16, 2026, https://pharmaceutical-journal.com/article/news/prenatal-exposure-to-paracetamol-linked-with-increased-risk-of-autism-and-adhd

  2. The Lancet Obstetrics, Gynecology, & Women's Health: Taking paracetamol during pregnancy does not increase risk of autism, ADHD or intellectual disabilities, confirms new gold-standard evidence review | EurekAlert!, accessed January 16, 2026, https://www.eurekalert.org/news-releases/1112663

  3. Acetaminophen's Role in Autism and ADHD: A Mitochondrial Perspective - MDPI, accessed January 16, 2026, https://www.mdpi.com/1422-0067/26/17/8585

  4. Prenatal Exposure to Acetaminophen and Risk for Attention Deficit Hyperactivity Disorder and Autistic Spectrum Disorder: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Cohort Studies - PubMed, accessed January 16, 2026, https://pubmed.ncbi.nlm.nih.gov/29688261/

  5. Prenatal and postnatal exposure to acetaminophen in relation to autism spectrum and attention-deficit and hyperactivity symptoms in childhood: Meta-analysis in six European population-based cohorts - PubMed Central, accessed January 16, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8542535/

  6. October 03, 2021 1 The European Network of Teratology Information Services, ENTIS: Position statement on acetaminophen (paraceta, accessed January 16, 2026, https://www.entis-org.eu/wp-content/uploads/2021/10/ENTIS-position-statement-on-acetaminophen-3.10.2021.pdf

  7. Paracetamol use during pregnancy — a call for precautionary action - ScienceOpen, accessed January 16, 2026, https://www.scienceopen.com/document?vid=5bb9a2a1-c342-4dbb-914b-e9d58917bdac

  8. Paracetamol use during pregnancy — a call for precautionary action - Aarhus University, accessed January 16, 2026, https://pure.au.dk/portal/en/publications/paracetamol-use-during-pregnancy-a-call-for-precautionary-action/

  9. Shelter from the storm: Acetaminophen (paracetamol) in pregnancy, urogenital malformations, and childhood neurodevelopment - PMC - NIH, accessed January 16, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9277736/

  10. Taking paracetamol during pregnancy does not increase risk of autism, ADHD or intellectual disabilities, accessed January 16, 2026, https://www.eurekalert.org/news-releases/1112802

  11. Review finds no evidence linking prenatal paracetamol use to ..., accessed January 16, 2026, https://www.contemporaryobgyn.net/view/review-finds-no-evidence-linking-prenatal-paracetamol-use-to-increased-risk-of-autism-adhd

  12. Maternal paracetamol (acetaminophen) use during pregnancy and risk of autism spectrum disorder and attention deficit/hyperactivity disorder in offspring: umbrella review of systematic reviews - PubMed, accessed January 16, 2026, https://pubmed.ncbi.nlm.nih.gov/41207796/

  13. Using acetaminophen during pregnancy may increase children's autism and ADHD risk, accessed January 16, 2026, https://hsph.harvard.edu/news/using-acetaminophen-during-pregnancy-may-increase-childrens-autism-and-adhd-risk/

  14. Acetaminophen, Pregnancy, and the Public Health Risk of Misleading Warnings, accessed January 16, 2026, http://amwa-doc.org/acetaminophen-pregnancy-and-the-public-health-risk-of-misleading-warnings/

  15. The Role of Maternal Immune Activation in the Pathogenesis of Autism: A Review of the Evidence, Proposed Mechanisms and Implications for Treatment - MDPI, accessed January 16, 2026, https://www.mdpi.com/1422-0067/22/21/11516

  16. Maternal Infection during Pregnancy and Autism Spectrum Disorders - PubMed Central, accessed January 16, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC4108569/

  17. Fever during pregnancy as a risk factor for neurodevelopmental disorders: results from a systematic review and meta-analysis - PubMed Central, accessed January 16, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8449704/

  18. Genetic Interplay Between Attention-Deficit/Hyperactivity Disorder and Pain Suggests Neurodevelopmental Pathways and Comorbidity Risk - NIH, accessed January 16, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12179596/

  19. Genetic Interplay Between Attention-Deficit/Hyperactivity Disorder and Pain Suggests Neurodevelopmental Pathways and Comorbidity Risk - PubMed, accessed January 16, 2026, https://pubmed.ncbi.nlm.nih.gov/40547906/

  20. Sibling Comparison Designs, accessed January 16, 2026, https://www.sdu.dk/-/media/files/om_sdu/institutter/ist/epid/courses/twins/papers/frisellsibs2012.pdf

  21. Invited Commentary: Sibling-Comparison Designs, Are They Worth the Effort? | American Journal of Epidemiology | Oxford Academic, accessed January 16, 2026, https://academic.oup.com/aje/article/190/5/738/5896191

  22. Study reveals no causal link between neurodevelopmental disorders and acetaminophen exposure before birth - NIH, accessed January 16, 2026, https://www.nih.gov/news-events/news-releases/study-reveals-no-causal-link-between-neurodevelopmental-disorders-acetaminophen-exposure-before-birth

  23. Paracetamol (Acetaminophen) and the Developing Brain - PMC - PubMed Central - NIH, accessed January 16, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8540524/

  24. Tylenol Autism Lawsuit: January 2026 Updates - Drugwatch.com, accessed January 16, 2026, https://www.drugwatch.com/drugs/tylenol/lawsuit/

  25. FDA Responds to Evidence of Possible Association Between Autism and Acetaminophen Use During Pregnancy, accessed January 16, 2026, https://www.fda.gov/news-events/press-announcements/fda-responds-evidence-possible-association-between-autism-and-acetaminophen-use-during-pregnancy

  26. Paracetamol and Pregnancy Safety Debate among Regulators - DrugCard: Comprehensive Literature Screening & Pharmacovigilance Solutions, accessed January 16, 2026, https://drug-card.io/blog/paracetamol-and-pregnancy-safety-debate-among-regulators/

  27. Paracetamol use in pregnancy | Therapeutic Goods Administration (TGA), accessed January 16, 2026, https://www.tga.gov.au/news/media-releases/paracetamol-use-pregnancy

  28. Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy - GOV.UK, accessed January 16, 2026, https://www.gov.uk/drug-safety-update/non-steroidal-anti-inflammatory-drugs-nsaids-potential-risks-following-prolonged-use-after-20-weeks-of-pregnancy

  29. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis - PubMed, accessed January 16, 2026, https://pubmed.ncbi.nlm.nih.gov/16638921/

  30. Non-steroidal anti-inflammatory drugs (NSAIDs): avoid use in pregnancy - Medsafe, accessed January 16, 2026, https://medsafe.govt.nz/profs/PUArticles/September2022/Non-steroidal-anti-inflammatory%20drugs-NSAIDs-avoid-use%20in-pregnancy.html

  31. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Drug Safety Communication - Avoid Use of NSAIDs in Pregnancy at 20 Weeks or Later | FDA, accessed January 16, 2026, https://www.fda.gov/safety/medical-product-safety-information/nonsteroidal-anti-inflammatory-drugs-nsaids-drug-safety-communication-avoid-use-nsaids-pregnancy-20

  32. expert reaction to review showing that taking paracetamol during pregnancy does not increase risk of autism, ADHD or intellectual disabilities | Science Media Centre, accessed January 16, 2026, https://www.sciencemediacentre.org/expert-reaction-to-review-showing-that-taking-paracetamol-during-pregnancy-does-not-increase-risk-of-autism-adhd-or-intellectual-disabilities/

Comments

bottom of page